64 results about "Platelet-poor plasma" patented technology

A composition, method, and use of microporous particles such as polysaccharide hemostat particle gels activates platelet rich plasma (PRP) or other platelet-containing substances. The composition may contain microporous polysaccharaide hemostats (MPH) mixed with platelet-rich plasma, platelet-poor plasma, blood, or the like. The method may contain mixing the MPH with platelet-rich plasma or other platelet-containing substance either by hand, in a device, or by applying the MPH directly to the wound before or after application of the platelet-containing substance. Alternatively, MPH can by applied directly to the bleeding wound, using the blood as a source of platelets.

Centrifuges are useful to, among other things, remove red blood cells from whole blood and retain platelets and other factors in a reduced volume of plasma. Platelet rich plasma (PRP) and or platelet poor plasma (PPP) can be obtained rapidly and is ready for immediate injection into the host. Embodiments may include valves, operated manually or automatically, to open ports that discharge the excess red blood cells and the excess plasma into separate receivers while retaining the platelets and other factors in the centrifuge chamber. High speeds used allow simple and small embodiments to be used at the patient's side during surgical procedures. The embodiments can also be used for the separation of liquids or slurries in other fields such as, for example, the separation of pigments or lubricants.

The invention discloses a method for testing platelet aggregation. A fully automatic platelet aggregometer is used for testing according to photoelectric turbidimetry. The method comprises the following test steps of: preparing a platelet aggregation inducer, putting prepared platelet rich plasma and platelet poor plasma into a sample disk device, instructing a sample adding needle to absorb the platelet poor plasma, injecting the platelet poor plasma into a test cup of a test core device and reading the transmittance data of a of a platelet poor plasma sample; instructing the sample adding needle to absorb the platelet rich plasma, injecting the platelet rich plasma into the test cup of the test core device and reading the transmittance data of a platelet poor plasma sample; instructing the sample adding needle to absorb the platelet aggregation inducer, injecting the platelet aggregation inducer into the test cup of the test core device and reading the transmittance data of an inductor sample; and calculating the maximum platelet aggregation rate of a tested blood sample and generating a test report according to input patient information.

Described herein are methods and compositions for the treatment of respiratory diseases such as, for example, exercise induced pulmonary hemorrhage. The methods include the use of compositions comprising platelet enriched plasma, for example, platelet rich plasma and/or platelet poor plasma, for treatment of respiratory diseases in humans and animals, in particular, equines, by administration to the respiratory system.

The invention relates to a method for measuring the platelet aggregation and a blood coagulation factor. In the method, a full-automatic coagulate blood analytical instrument is used, the platelet aggregation is measured by using photoelectric turbidimetry and the blood coagulation factor is measured by using a double magnetic circuit and bead method. The method comprises the following measuring steps of: preparing a platelet aggregation inductive agent, platelet rich plasma and platelet poor plasma; respectively reading light transmittance data of a platelet poor plasma sample and light transmittance data of a platelet rich plasma sample as well as light transmittance data of the platelet rich plasma during the forming process of the platelet aggregation within the specified time; calculating the platelet aggregation rate of the measured blood sample; absorbing the platelet poor plasma and injecting the platelet poor plasma in a hemagglutination cup; absorbing the selected reagent according to a test program and injecting the selected reagent into the hemagglutination cup; automatically monitoring the amplitude of a steel bead; and generating a test report by using measuring results of the platelet aggregation and the blood coagulation factor according to input information of patients.

Centrifuges are useful to, among other things, remove red blood cells from whole blood and retain platelets and other factors in a reduced volume of plasma. Platelet rich plasma (PRP) and or platelet poor plasma (PPP) can be obtained rapidly and is ready for immediate injection into the host. Embodiments may include valves, operated manually or automatically, to open ports that discharge the excess red blood cells and the excess plasma into separate receivers while retaining the platelets and other factors in the centrifuge chamber. High speeds used allow simple and small embodiments to be used at the patient's side during surgical procedures. The embodiments can also be used for the separation of liquids or slurries in other fields such as, for example, the separation of pigments or lubricants.

The present invention is a method to accelerate the coagulation of blood through the application of inorganic materials. Any solid that can be used to activate the coagulation of platelet-poor plasma in the APTT clinical test or whole blood in the ACT clinical test has been found to be effective as a coagulation accelerator in vivo. Typical materials that can be used for in-vivo clotting include diatomaceous earth, glass powder or fibers, precipitated or fumed silica, and calcium exchanged permutites. Thes materials can be used in an aqueous slurry, dry powder or dehydrated forms, and can also be bound with suitable organic or inorganic binders and/or contained in a variety of forms.

A method and kit to produce activated autologous platelet rich and platelet poor plasma (AAPRPP) and methods of use to treat pain. The method to produce AAPRPP generally comprising (1) obtaining whole blood from patient; (2) centrifuging whole blood in a collection tube; (3) extracting platelet rich and platelet poor plasma mixture from collection tube; and (4) transferring platelet rich and platelet poor plasma mixture to an activation tube containing at least one platelet aggregator and at least one platelet activator to obtain a resulting platelet concentration. The method to treat pain generally comprising producing AAPRPP and extracting contents of activation tube into a standard syringe then injecting AAPRPP at or near the nerve group responsible for the affected anatomical area.

Systems and methods are provided for depleting platelets from blood. The system includes a multi-stage blood separation chamber in which blood is separated into red blood cells and platelet-rich plasma. The platelet-rich plasma is conveyed from a first stage of the chamber to a second stage, where it is separated into platelets and platelet-poor plasma. The platelet-poor plasma is conveyed out of the chamber while the platelets are allowed to accumulate in the second stage of the chamber. When a controller of the system has determined that the maximum chamber capacity of platelets has been accumulated in the second stage of the chamber, the platelets are conveyed out of the chamber to a waste container. The cycle of separating blood into its components, accumulating platelets in the chamber, and then flushing the platelets from the chamber is repeated until a target platelet concentration of the blood is achieved.

Platelet rich plasma and/or platelet concentrate is prepared by placing whole blood in a first chamber of a sterile processing disposable having two chambers. The processing disposable is subjected to a first centrifugation to separate red blood cells, and the resulting platelet rich plasma supernatant is decanted to the second chamber. The processing disposable is subjected to a second centrifugation to concentrate platelets. A volume of the platelet poor plasma supernatant in the second chamber is removed, and the platelets are re-suspended in the remaining plasma. The second chamber may contain anticoagulant to preclude aggregation of the platelets.

The invention discloses a method for detecting an activated blood coagulation factor XI in human intravenous immunoglobulin. The method comprises the steps as follows: (1) mixing an IVIG (intravenous immunoglobulin) sample with specially-preprocessed platelet-poor plasma (PPP); (2) adding a thrombin specific fluorogenic substrate with a phospholipid agent into a reaction system; (3) adding an initiation factor for starting a TGT (thrombin generation test), wherein the initiation factor comprises a calcium ion source and the phospholipid agent; (4) obtaining a thrombin generation curve providing parameters by the optimized reaction system; and (5) negatively correlating the peak time of thrombin (TTP) of the detected sample with the FXIa (activated blood coagulation factor XI) level in the sample. The FXIa level in the detected sample can be indirectly obtained by comparing the TTP of the detected sample with that of an FXIa standard sample. The method is suitable for detecting residual micro FXIa in human intravenous immunoglobulin (IVIG) products and is used for extracorporal evaluation of thrombosis risk of related products.

The present invention provides a non-liquid biomaterial that may be used as a surgical sealant, a suture support, a blood flow controller, an adhesion reducing agent, an adhesion preventing agent, a tissue support, a tissue filler, a wound dressing or a combination thereof. The non-liquid biomaterial may comprise a blood derived material such as plasma, platelet poor plasma, platelet rich plasma or a material derived from blood containing tissue aspirate, such as bone marrow aspirate, a protein binding agent and a polymerizing agent. Methods for making and using the non-liquid biomaterial are also provided.

The present invention provides methods for identifying candidate biomarkers in the plasma microparticle proteome. It also provides methods for isolating, identifying, and analyzing microparticles derived from plasma, particularly platelet-poor plasma.

The invention provides a sealed-type platelet rich plasma separating assembly and method. The separating method involves a separating pipe, a platelet collecting device and several collecting devices,wherein the separating pipe is connected with the platelet collecting device through a main collecting pipe; the main connecting pipe is further provided with several branch connecting pipes, and theconnecting devices are communicated with the main connecting pipe through the branch connecting pipes respectively. The separating method comprises the steps of blood drawing, first separating, erythrocyte separating, second separating, platelet poor plasma separating, and platelet rich plasma separating. By means of the sealed-type platelet rich plasma separating assembly and method, the risk that blood is exposed and contaminated in the separation and preparation process is avoided; not only is the platelet recycling rate high, but also the sealed-type platelet rich plasma separating assembly is safe and convenient to use.